BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

@article{King2011BUILD3AR,
  title={BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.},
  author={Talmadge E. King and Kevin K Brown and Ganesh Raghu and Roland M. du Bois and David A. Lynch and Fernando Jos{\'e} Rodr{\'i}guez Mart{\'i}nez and Dominique Valeyre and Isabelle Leconte and Adele Morganti and S{\'e}bastien Roux and Juergen Behr},
  journal={American journal of respiratory and critical care medicine},
  year={2011},
  volume={184 1},
  pages={
          92-9
        }
}
  • T. King, K. Brown, +8 authors J. Behr
  • Published 2011
  • Medicine
  • American journal of respiratory and critical care medicine
RATIONALE A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend to delayed IPF worsening or death. [...] Key MethodMETHODS Prospective, randomized (2:1), double-blind, placebo-controlled, event-driven, parallel-group, morbidity-mortality trial of bosentan in adults with IPF of less than 3 years' duration, confirmed by surgical lung biopsy, and without extensive honeycombing on high-resolution computed tomography.Expand
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
TLDR
Although many outcome variables were stable, bosentan did not reduce the frequency of clinically important worsening and these data do not support the use of endothelin receptor antagonists as therapy for ILD secondary to SSc. Expand
Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial
TLDR
Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations and the study was terminated early. Expand
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
  • V. Cottin
  • Medicine
  • European Respiratory Review
  • 2012
TLDR
Evidence of beneficial effects of pirfenidone treatment was observed with regard to several secondary end-points, including progression-free survival time, categorical FVC change, and mean change from baseline to week 72 in 6MWT distance. Expand
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study
TLDR
Bosentan tended to improve prognosis and ADL without worsening respiratory failure in IPF patients with borderline or less severe PH and completely organized honeycomb lung alone, and was associated with no increase but a trend toward a decrease in adverse events and an improvement in respiratory status. Expand
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
TLDR
These trials showed that treatment with nintedanib slowed the rate of forced vital capacity (FVC) decline but no significant difference was observed in the St George's Respiratory Questionnaire (SGRQ) score, and the addition of sildenafil to nintEDanib treatment does not improve outcomes to a greater extent than monotherapy with nintsendanib. Expand
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan
TLDR
Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations and the study was terminated early. Expand
Pirfenidone in idiopathic pulmonary fibrosis
TLDR
Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF. Expand
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
TLDR
Long-term exposure to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in each treatment group, and the primary objective was not met. Expand
Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
  • D. Lederer
  • Medicine
  • European Respiratory Journal
  • 2013
TLDR
The MUSIC trial investigators found that macitentan was not effective for the treatment of IPF, with no meaningful differences in forced vital capacity (FVC), the study's primary end-point, or diffusing capacity of the lung for carbon monoxide at 1 year between allocation arms. Expand
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial
TLDR
The EME-TIPAC trial is designed to test the hypothesis that treating IPF patients with co-trimoxazole will increase the time to death, transplant or first non-elective hospital admission compared to standard care. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.
TLDR
In this exploratory study in patients with clinically progressive IPF, etanercept was well tolerated and, although there were no differences in the predefined endpoints, a decreased rate of disease progression was observed on several measures. Expand
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study
TLDR
Bosentan administration does not seem to induce clinically relevant gas exchange abnormalities in idiopathic pulmonary fibrosis patients, and the secondary parameters was not significantly changed either at week 2 or at the end of the study period. Expand
Pirfenidone in idiopathic pulmonary fibrosis
TLDR
Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF. Expand
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
TLDR
It is concluded that mortality is the most inclusive end point for future trials of IFN- gamma1b in patients with IPF, and that a > 10% decrement in the percentage of predicted FVC represents a valid measure of disease progression. Expand
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
TLDR
Observations from exploratory analyses suggested benefits of bosentan on HRQoL among patients who had undergone surgical lung biopsy for diagnosis, and they merit further investigation. Expand
High-dose acetylcysteine in idiopathic pulmonary fibrosis.
TLDR
Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone. Expand
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
TLDR
Proportional hazards analysis and time-dependent receiver operating characteristic methodology were used and marginal changes in FVC and DL,CO in IPF and fibrotic NSIP did not provide useful prognostic information. Expand
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
TLDR
The data suggest that a gradual, progressive decline does not occur in many patients with idiopathic pulmonary fibrosis, thereby supporting the need for early referral for lung transplantation. Expand
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
TLDR
The novel post-marketing surveillance captured targeted safety data from the majority of patients and confirmed that the incidence and severity of elevated aminotransferase levels in clinical practice was similar to that reported in clinical trials. Expand
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
TLDR
Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension. Expand
...
1
2
3
4
5
...